Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

Neomorphic chromatin engagement and epigenetic reprogramming by the IKZF1 N159Y tandem duplication mutant in b-acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 1480.

https://doi.org/10.1182/blood-2025-1480

Published: 2025

Journal Articles

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

Blood (2025) 146 (Supplement 1): 31.

https://doi.org/10.1182/blood-2025-31

Published: 2025

Journal Articles

Molecular subtypes and BH3 mimetic synergy with anti-leukemia agents in T-cell acute lymphoblastic leukemia

Satoshi Yoshimura, Yizhen Li, Xu Yang, Christian Meyer, Guoqing Du, Yu-Chih Hsiao, Zhenhua Li, Wenjian Yang, Courtney Andersen, Caner Saygin, Seth Karol, Kathrin Bernt, Jiyang Yu, Wendy Stock, David Teachey, Marina Konopleva, Jun J. Yang

Blood (2025) 146 (Supplement 1): 5081.

https://doi.org/10.1182/blood-2025-5081

Published: 2025

Journal Articles

Mitochondrial hyperactivity predicts chemotherapy relapse and venetoclax resistance in pediatric B-cell acute lymphoblastic leukemia

Jingliao Zhang, Peng Wu, Yongjuan Duan, Wenyu Yang, Xiaofan Zhu, Jun J. Yang, Yingchi Zhang

Blood (2025) 146 (Supplement 1): 3361.

https://doi.org/10.1182/blood-2025-3361

Published: 2025

Journal Articles

Impact of noncoding tandem repeat sequence on TPMT function and thiopurine metabolism in children with ALL

Jason Xu, Wenjian Yang, Kristine Crews, Alejandro Molinelli, Sima Jeha, Ching-Hon Pui, Seth Karol, Hiroto Inaba, Jun J. Yang

Blood (2025) 146 (Supplement 1): 332.

https://doi.org/10.1182/blood-2025-332

Published: 2025

Journal Articles

Increased yield of recurrent structural variants (SVs) in Ph-like B-cell acute lymphoblastic leukemia (B-ALL) using a streamlined clinical whole-genome sequencing (WGS) assay

Blood (2025) 146 (Supplement 1): 1590.

https://doi.org/10.1182/blood-2025-1590

Published: 2025

Journal Articles

Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survival

Blood (2025) 146 (Supplement 1): 444.

https://doi.org/10.1182/blood-2025-444

Published: 2025

Journal Articles

ALL-pharmacotyping data portal: An open-source platform for exploring genomics of leukemia drug susceptibility and resistance

Karishma Gangwani, Satoshi Yoshimura, Zhenhua Li, Robin Paul, Wenjian Yang, Congyu Lu, Jian Wang, Andrew Willems, Gavriel Matt, Edgar Sioson, Colleen Reilly, Airen Zaldivar Peraza, Aleksandar Acić, Shawn Lee, Jun J. Yang, Xin Zhou

Blood (2025) 146 (Supplement 1): 5139.

https://doi.org/10.1182/blood-2025-5139

Published: 2025

Journal Articles

Relapsed acute lymphoblastic leukemia treated with venetoclax and navitoclax: Results of the raven study in children and young adults with relapsed/ refractory ALL

Seth Karol, Maria Luisa Sulis, Yinmei Zhou, Satoshi Yoshimura, Wenjian Yang, Qingsong Gao, Matthew Rees, Hiroto Inaba, Raul Ribeiro, Cheng Cheng, Charles Mullighan, Jun J. Yang, Ching-Hon Pui

Blood (2025) 146 (Supplement 1): 5126.

https://doi.org/10.1182/blood-2025-5126

Published: 2025

Journal Articles

Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin

Blood (2025) 146 (4): 471–481.

https://doi.org/10.1182/blood.2024028215

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome

Blood (2025) 145 (23): 2685–2700.

https://doi.org/10.1182/blood.2024027270

Published: 2025

Includes: Supplemental data

Journal Articles

STAT1-mediated interferon signatures are associated with preclinical JAK inhibitor sensitivity in T-ALL

Blood (2025) 145 (23): 2793–2798.

https://doi.org/10.1182/blood.2025028566

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL

Blood (2025) 145 (17): 1890–1902.

https://doi.org/10.1182/blood.2024026381

Published: 2025

Includes: Supplemental data

Journal Articles

DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia

Blood (2025) 145 (11): 1182–1194.

https://doi.org/10.1182/blood.2024026085

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes in patients with ETV6 :: RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies

Katelyn Purvis, Yinmei Zhou, Seth E. Karol, Jeffrey E. Rubnitz, Raul C. Ribeiro, Shawn Lee, Jun J. Yang, W. Paul Bowman, Lu Wang, Stephanie B. Dixon, Kathryn G. Roberts, Qingsong Gao, Cheng Cheng, Charles G. Mullighan, Sima Jeha, Ching-Hon Pui, Hiroto Inaba

Blood (2025) 145 (2): 190–201.

https://doi.org/10.1182/blood.2024024936

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and Feasibility of Blinatumomab As Frontline Therapy for Pediatric Patients with B-Acute Lymphoblastic Leukemia and Lymphoma: St. Jude Total Therapy Study XVII

Caitlyn Duffy, Elizabeth Dang, Zhou Yinmei, Jessica Bell, Nickhill Bhakta, Meret Henry, Kenneth Matthew Heym, Sima Jeha, Norman J. Lacayo, Seth E. Karol, Seong Lin Khaw, Raul C. Ribeiro, Deborah E. Schiff, Charles G. Mullighan, Jun J. Yang, Cheng Cheng, Ching-Hon Pui, Hiroto Inaba

Blood (2024) 144 (Supplement 1): 4208.

https://doi.org/10.1182/blood-2024-209284

Published: 2024

Journal Articles

Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL

Blood (2024) 144 (Supplement 1): 1464.

https://doi.org/10.1182/blood-2024-211090

Published: 2024

Journal Articles

EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

Carolin S. Escherich, Zhenhua Li, Kelly R. Barnett, Yizhen Li, Megan Walker, Wenjian Yang, Xin Huang, Jiyang Yu, Wendy Stock, Elisabeth Paietta, Marina Konopleva, Steven M. Kornblau, Mark R. Litzow, Hiroto Inaba, Ching-Hon Pui, Mignon L. Loh, Daniel Savic, Jun J. Yang

Blood (2024) 144 (Supplement 1): 830.

https://doi.org/10.1182/blood-2024-198800

Published: 2024

Journal Articles

Genome-Wide Association Study of Acute Lymphoblastic Leukemia in Hispanic/Latino Children Identifies a Putatively Novel Risk Locus at Chromosome 5q31.1

Tanxin Liu, Jalen Langie, Wenjian Yang, Libby Morimoto, Xiaomei Ma, Catherine Metayer, Philip J Lupo, Michael E. Scheurer, Jun J. Yang, Joseph L. Wiemels, Charleston W.K. Chiang, Adam J. de Smith

Blood (2024) 144 (Supplement 1): 317.

https://doi.org/10.1182/blood-2024-208796

Published: 2024

Journal Articles

Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma

Blood (2024) 144 (Supplement 1): 313.

https://doi.org/10.1182/blood-2024-203827

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Neomorphic chromatin engagement and epigenetic reprogramming by the IKZF1 N159Y tandem duplication mutant in b-acute lymphoblastic leukemia

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

Molecular subtypes and BH3 mimetic synergy with anti-leukemia agents in T-cell acute lymphoblastic leukemia

Mitochondrial hyperactivity predicts chemotherapy relapse and venetoclax resistance in pediatric B-cell acute lymphoblastic leukemia

Impact of noncoding tandem repeat sequence on TPMT function and thiopurine metabolism in children with ALL

Increased yield of recurrent structural variants (SVs) in Ph-like B-cell acute lymphoblastic leukemia (B-ALL) using a streamlined clinical whole-genome sequencing (WGS) assay

Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survival

ALL-pharmacotyping data portal: An open-source platform for exploring genomics of leukemia drug susceptibility and resistance

Relapsed acute lymphoblastic leukemia treated with venetoclax and navitoclax: Results of the raven study in children and young adults with relapsed/ refractory ALL

Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin

Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome

STAT1-mediated interferon signatures are associated with preclinical JAK inhibitor sensitivity in T-ALL

Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL

DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia

Outcomes in patients with ETV6 :: RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies

Safety and Feasibility of Blinatumomab As Frontline Therapy for Pediatric Patients with B-Acute Lymphoblastic Leukemia and Lymphoma: St. Jude Total Therapy Study XVII

Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL

EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

Genome-Wide Association Study of Acute Lymphoblastic Leukemia in Hispanic/Latino Children Identifies a Putatively Novel Risk Locus at Chromosome 5q31.1

Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only